Skip to main content
. Author manuscript; available in PMC: 2012 Sep 7.
Published in final edited form as: Clin Cancer Res. 2008 Mar 1;14(5):1377–1385. doi: 10.1158/1078-0432.CCR-07-1516

Fig. 2.

Fig. 2

Biodistribution. Dunning prostate R3327-AT1tumor-bearing rats were injected with 185 kBq of [74As]bavituximab or [74As]rituximab i.v. Groups of four animals were sacrificed by exsanguination and perfusion 48 or 72 h after injection. A, tumor-to-liver ratios for rats sacrificed after 48 and 72 h after injection with [74As]rituximab (black) or [74As]bavituximab (dots). B, corresponding tumor to muscle ratios. C, specific localization of bavituximab/rituximab in major organs after 48 h (narrow hatched) and 72 h (broad hatched). Specific localization is calculated as the ratio of the % ID/gram for [74As]bavituximab to the % ID/gram for [74As]rituximab in tumor and normal tissues. At 72 h, the uptake of bavituximab was significantly higher in tumor than liver or muscle (P < 0.001).